Professor Kranzler is the Benjamin Rush Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine
Tel Aviv, Israel / Vancouver, Canada, March 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the appointment of Professor Henry R. Kranzler, M.D., as the newest member of its Scientific Advisory Board (“SAB”).
Professor Kranzler is the Benjamin Rush Professor of Psychiatry, and Director of the Center for Studies of Addiction, at the University of Pennsylvania’s Perelman School of Medicine, which was ranked #6 in 2023 on the US News & World Report rankings. His research focuses on the genetics and pharmacological treatment of substance dependence, with emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health.
“Clearmind’s drug candidates are novel agents that have the potential to alter substantially the landscape of alcohol and other substance use disorder treatment,” said Professor Kranzler, “The company’s forward-looking approach to medications development promises to yield important new discoveries.”
Professor Kranzler has authored or co-authored more than 600 journal articles, book chapters, and books, is a member of the editorial board of three peer-review journals as well as the editor of Alcohol: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach.
“We are honored to have a world-renowned figure like Professor Kranzler join our SAB alongside other prestigious professionals,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Professor Kranzler is an expert on addiction medicine, especially genetic and pharmacological aspects of alcohol and other substance use disorders, aligning perfectly with Clearmind’s mission. We are thrilled and look forward to his contributions to Clearmind’s beneficial work given his stature, vast knowledge and expertise in the addiction field.”
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of 13 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY”.
For further information visit: https://www.clearmindmedicine.com or contact:
Telephone: (604) 260-1566
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. In addition, we cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to us. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F filed with the SEC on February 6, 2023. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.